BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end

BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonists

Internally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing

Read more at globenewswire.com